Phase II - IV Clinical

Howard Schwartz, Medical Director of QPS Miami Research Associates Co-Authors Daclatasvir-Sofosbuvir Combination HCV Trial Published in The New England Journal Of Medicine - February, 2014

An estimated 3% of the world’s population - more than 170 million people - are infected with the hepatitis C virus (HCV). Most infections become chronic. Chronic infection is incurable in many patients and leads to cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). Current therapy for chronic hepatitis C includes protease inhibitors in conjunction with pegylated interferon and ribavirin.

The goal of therapy is to slow or halt progression of liver fibrosis and prevent the development of cirrhosis. Our understanding of HCV and how to treat it is growing rapidly. Multidrug regimens using new therapies in combination with existing medications have given hope to millions of patients worldwide. Please read the original article here, co-authored by Howard Schwartz, Medical Director of QPS MRA. It may herald a new era of HCV therapy, wherein ribavirin is no longer a required constituent in every oral, direct-acting antiviral regimen.

20 years in pharma R&D navigation